Introduction
the combination of 2 drugs with chemotherapy based on platinum drugs on the stage (Maione et al., 2011) . Cisplatin (DDP) is the first generation of platinum drugs, which has become the basic drug for treating advanced solid tumors like NSCLC, etc. (Rinaldi et al., 2006) . However, its clinical application is limited due to severe gastrointestinal responses, renal toxicity and neurotixicity. Nedaplatin (NDP) is a new anti-tumor drug derived from DDP, which has similar action mechanisms to DDP, but also revealed stronger anti-tumor effect and lower toxic and adverse responses in animal research (Kameyama et al., 1990) . This study analyzed and compared the efficacy and safety of NDP or DDP concomitant with chemotherapies in treating advanced NSCLC, hoping to provide references for the reasonable clinical application of NDP in the future. 
Materials and Methods
General data A total of 619 patients with advanced NSCLC hospitalized in our hospital from October, 2009 to July, 2011 were selected, in which there were 391 males and 228 females aging from 21 years to 81 years with average age being (55.65±8.50) years. And in this study, there were 522 patients with initial treatment, 97 with re-treatment, 220 with squamous carcinoma, 399 with adeno-carcinoma and 426 with surgeries during treatment. According to pathological stages, 76, 90, 119, 99 and 235 patients were in phases Ⅰ, Ⅱ, Ⅲa, Ⅲb and Ⅳ, respectively.
Layered Groups
The selected patients were randomly divided into NDP group (n=294) and DDP group (n=325). Chemotherapeutic protocols (CP/DP/GP/NP/TP) containing NDP/DDP were administrated to both groups and there were no statistically significant differences in general data (P>0.05), as shown in Table 1 
Observational indexes
Short-term efficacy, survival time and toxic and adverse responses in both groups were observed after the followup was ended on November, 23th, 2012. Moreover, the 2 groups were further divided to evaluate clinical efficacies according to initial and re-treatment, pathological patterns, types of combined chemotherapeutic protocols and tumor stages.
Efficacy evaluation criteria
Therapeutic efficacy was evaluated according to 
Statistical data analysis
SPSS 10.0 software was adopted for all data analysis, whereas t-test was applied for the comparison of means of both groups and measurement date was expressed as mean±standard deviation (χ±s). P<0.05 was regarded as the difference was statistically significant.
Results

Short-term efficacy
In NDP group, there were 12 CR, 131 PR, 137 SD and 14 PD, with ORR and DCR being 48.6% and 95.2%, while in DDP group, CR, PR, SD and PD were 10, 104, 176 and 35, with ORR and DCR being 35.1% and 89.2%, respectively, showing that ORR and DCR were evidently higher in NDP group than in DDP group, and the differences were significant (P<0.01), as shown in Table 2 .
Layered clinical efficacies
The 2 groups were further divided to evaluate clinical efficacies according to initial and re-treatment, pathological patterns, types of combined chemotherapeutic protocols and tumor stages. As shown in Table 3 , ORR and DCR in NDP group were obviously higher than in DDP group in patients with initial treatment and squamous carcinoma (P<0.05 or P<0.01), while ORR was apparently higher in patients with adeno-carcinoma, GP/TP, and in phase Ⅲa (P<0.05 or P<0.01), and DCR was markedly higher in patients in phase Ⅲb in NDP group than in DDP group (P<0.05).
Survival time
Survival time of 619 patients was statistically analyzed, which indicated that mean survival time and medium survival time (MST) in NDP group were (17.115±0.926) months and (14.783±1.092) months, and were (21.391±2.049) months and (13.502±2.327) months in DDP group, respectively, demonstrating that MST was longer in NDP group than in DDP group, and the difference was significant (P<0.01) ( Table 4, Table 5 and Figure 1) . Table 8 is showing the adverse responses of 2 groups, which demonstrated that the rates of decreased hemoglobin, increased creatinine, nausea and vomiting were markedly lower (P<0.05 or P<0.01) but indirect elevated bilirubin was evidently higher in NDP group than in DDP group (P<0.05).
Adverse responses
Discussion
Incidences of lung cancer in China have been increasingly more serious for the past few years, in which NSCLC accounts for>80%, including large cell carcinoma, adeno-carcinoma and squamous carcinoma (Govindan et al., 2006; Liu et al., 2013; Kim et al., 2014) . Surgery is one of the optimal therapeutic methods for early treatment, but it is difficult to perform because there is no specific or obvious clinical symptom in early stage (Yu et al., 2013; Oven Ustaalioglu et al., 2013; Mandal et al., 2013) . When diagnosed, only < 20% NSCLC patients could receive surgeries and fewer with radiotherapy, and most are in advanced ones with distant metastasis who missed the optimal surgical opportunities except the systemic chemotherapies. Studies demonstrated that the third generation of cytotoxic drugs concomitant with cisplatins and chemotherapies were the optimal choices for treating middle and advanced NSCLC (Sugiyama et al., 2011; Terret et al., 2011) , which played a critical and important role in controlling disease progression, alleviating clinical symptoms, improving patients' quality of life (QOL) and prolonging their survival time, etc.. However, appropriate chemotherapeutic protocols and drugs are extremely important due to frequently occurred distant metastasis and recurrence according to complex biological properties and poor immunity in old and weak patients.
DDP is the first generation of anti-tumor drugs with non-specific cycle in cisplatins that came to market in USA in 1979, which could dissociate chlorine in low chlorine environment after being administrated to form hydrated cation of cisplatin, and combine with N7s on DNA binding sites A and G to form covalent bond. After combination, the formation of intra-strand and inter-strand cross-links as well as the those of DDP and DNA-protein molecules reversed or un-winded DNA strands, which inhibit the republication of DNA, leading to cellular apoptosis (Arriagada et al., 2004; Scagliotti et al., 2008) . One study compared the efficacy and safety of DDP or carboplatin (CBP) in the treatment of NSCLC, revealing that the short-term efficacy of DDP was markedly better than CBP, but there was no significant difference in improvement of survival time, whereas the analysis DOI:http://dx.doi.org/10.7314/APJCP.2014.15.2 
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of subgroups showed that DDP had better survival advantages than CBP when concomitant with the third generation of chemotherapeutic drugs (Hotta et al., 2004) . However, another study indicated that CBP was superior to DDP in treating patients administrated with the third generation of cytotoxic drugs and those with squamous carcinoma, and it was predicated to be associated with the stronger renal toxicity and gastrointestinal responses, which severely influenced patients' QOL, especially those with renal dysfunction and poor compliances, tolerance and general condition, and inhibit the effective application of DDP in clinic.
NDP is the second generation of anti-tumor agent in cisplatins and has similar actions to DDP, that is, it could react with DNA nucleosides, produce compound of nucleosides-cisplatins and blockage the republication of DNA to achieve its anti-tumor effect (Alberto et al., 2009; Teramoto et al., 2012) . However, NDP has become increasingly more important in treating NSCLC in that it has no complete cross-tolerance, but is 10 folds in watersolubility than DDP. One study indicated that ORR and DCR of NDP concomitant with docetaxel in the treatment of advanced NSCLC were 50.0% and 75%, respectively, in which patients with squamous carcinoma had evidently higher ORR and less adverse responses with slight nonhematological adverse responses and good tolerance than those with adeno-carcinoma, suggesting that NDP concomitant with docetaxel were more effective and tolerable in advanced NSCLC patients with squamous carcinoma than those with adeno-carcinoma (Yang et al., 2012) . However, another clinical research of NDP/ gemcitabine comparing with CBP/gemcitabine in treating advanced NSCLC showed that there were no significant differences in MST and ORR in 2 groups, and the main toxic and adverse responses contained leucopenia, anemia and thrombopenia, etc., which had no statistically significant difference (Niioka et al., 2007) .
This study compared and analyzed the differences of efficacy and safety between NDP and DDP concomitant with CP, DP, GP, NP and TP in treating advanced NSCLC, which indicated that NDP group was evidently higher than DDP group in ORR and DCR in that ORR and DCR were 48.6% and 95.2% in NDP group, but were 35.1% and 89.2% in DDP group, respectively, and NDP group was obviously higher than DDP group in ORR and/or DCR of patients with initial treatment, squamous carcinoma, GP/TP and in stage Ⅲa/Ⅲb, demonstrating that NDP concomitant with chemotherapy were more appropriate for patients with initial advanced lung squamous carcinoma. Survival time of 619 patients was also statistically analyzed in this study, which found that MST was markedly longer in NDP group than in DDP group. For adverse responses, the main toxic and adverse responses in NDP group were hepatorenal functional injury and hematological toxicity with slight gastrointestinal responses, significantly lower than DDP group in the rates of reduced hemoglobin, increased creatinine, and nausea and vomiting.
To sum up, NDP concomitant with chemotherapy is more effective than DDP in the treatment of advanced NSCLC, and is more appropriate to patients with lung squamous carcinoma. Additionally, hematological toxicity and gastrointestinal responses in NDP group were alleviated more significantly than in DDP group with favorable tolerance, which improved their compliances. According to comprehensive consideration of clinical efficacy, rates and severity of adverse response and patients' tolerance, NDP is more easily to be accepted by physicians and patients, which has extensive clinical applicable prospect in treating patients with advanced NSCLC, especially those with lung suqamous carcinoma, deserving to be further concerned in clinic.
